Allergan Aesthetics Says FDA Approves SKINVIVE By JUVEDERM
(RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced Monday the U.S. FDA approval of SKINVIVE by JUVEDERM to improve skin smoothness of the cheeks in adults over the age of 21.
SKINVIVE by JUVEDERM is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness available in the U.S. with results lasting through six months with optimal treatment.
SKINVIVE by JUVEDERM is a smooth, injectable HA gel that contains a small amount of local anesthetic (lidocaine).1 Unlike other facial injectables that enhance and augment the treatment area, SKINVIVE by JUVEDERM improves skin quality in the cheeks by smoothing the skin and increasing hydration.
SKINVIVE by JUVEDERM is a specialized, smooth, hydrating gel that flows easily into the skin and is approved for all Fitzpatrick Skin Types I-VI, lightest to darkest, addressing an important unmet need in the skin quality category.
Allergan Aesthetics anticipates that SKINVIVE by JUVEDERM will be broadly commercially available within the next six months.
AbbVie Boosts FY24 Outlook - Update
AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis
AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients
AbbVie To Acquire Landos Biopharma At $20.42/share In Cash
AbbVie Appoints President And COO Robert Michael To Addl. Role Of CEO
AbbVie To Acquire ImmunoGen For $31.26/shre In All-cash Deal Of About $10.1 Bln
AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin
